Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 23.00 GBp
Change Today +0.25 / 1.10%
Volume 293.1K
EKF On Other Exchanges
Symbol
Exchange
London
Berlin
OTC US
As of 11:35 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

ekf diagnostics holdings plc (EKF) Snapshot

Open
22.00 GBp
Previous Close
22.75 GBp
Day High
23.00 GBp
Day Low
22.00 GBp
52 Week High
05/6/14 - 34.00 GBp
52 Week Low
04/2/15 - 19.00 GBp
Market Cap
97.1M
Average Volume 10 Days
267.1K
EPS TTM
-0.02 GBp
Shares Outstanding
422.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EKF DIAGNOSTICS HOLDINGS PLC (EKF)

Related News

No related news articles were found.

ekf diagnostics holdings plc (EKF) Related Businessweek News

No Related Businessweek News Found

ekf diagnostics holdings plc (EKF) Details

EKF Diagnostics Holdings plc is engaged in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the United Kingdom, the United States, Germany, Poland, Russia, Ireland, and Asia. The company offers near patient analyzers for the measurement of glucose, lactate, hemoglobin, hematocrit, and HbA1c. Its products include glycated hemoglobin analyzers, such as Quo-Test, Quo-Lab, and Biosen HbA1c analyzers for monitoring diabetes; hemoglobin analyzers consisting of Hemo Control and Hemo Vet, which are point of care devices to provide results for hemoglobin and hematocrit, as well as STAT-Site M Hgb, a hand-held device for blood screening programs; and glucose analyzers comprising Biosen C-Line and S-Line glucose and lactate analyzers, and Lactate Scout+, a hand-held lactate analyzer. The company also provides rapid testing services, including pregnancy tests, such as True20, QuPID, and QuStick for urine only or urine and serum pregnancy testing; and infectious diseases tests, such as H. Pylori, RELY Mono, RELY and Strep A, and QuStick for the detection of pathonogenic micro-organisms, such as bacteria, parasites, viruses, and fungi. In addition, it offers clinical chemistry reagents; and biomarker diagnostic kits used by researchers and clinicians, as well as molecular diagnostic test kits, which are focused on applications within oncological research. The company sells its products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Founded in 1990

ekf diagnostics holdings plc (EKF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 297.0K GBP
Executive Chairman
Total Annual Compensation: 45.0K GBP
Finance Director, Secretary and Executive Dir...
Total Annual Compensation: 19.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 214.0K GBP
Compensation as of Fiscal Year 2013.

ekf diagnostics holdings plc (EKF) Key Developments

EKF Diagnostics Holdings plc Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2014

EKF Diagnostics Holdings plc reported audited consolidated earnings results for the year ended December 31, 2014. For the year, the company’s revenues were up 26% to £40.1 million against £31.8 million a year ago. Adjusted EBITDA was up 31% to £6.3 million against £4.8 million a year ago. Operating loss was £2.5 million against operating profit of £2.4 million a year ago. EBITDA before exceptional items and share-based payments was £6.257 million against £4.824 million a year ago. Loss before income tax was £4.028 million against profit before income tax of £0.607 million a year ago. Loss attributable to owners of the parent was £5.689 million or £1.50 per diluted share against £1.126 million or £0.41 per diluted share a year ago. Net cash used in operating activities was £4.744 million against net cash generated by operating £2.007 million a year ago. Purchase of property, plant and equipment was £1.038 million against £1.185 million a year ago. Purchase of intangibles was £1.595 million against £1.097 million a year ago.

EKF Diagnostics Holdings plc Announces a Major 18 Month Collaboration in the US, for its PrecisionPath Technology

EKF Diagnostics Holdings plc announced a major 18 month collaboration in the US, using the company's PrecisionPath™ technology to provide genetic profiles of cancer tumours, which, if successful, will lead to greatly improved treatment decisions for colon cancer patients. EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces a major 18 month collaboration in the US, using the Company's PrecisionPath™ technology to provide genetic profiles of cancer tumours, which, if successful, will lead to greatly improved treatment decisions for colon cancer patients. The collaboration brings together EKF's subsidiary Selah Genomics; Greenville Health Systems, one of the leading cancer institutes in the US; DecisionQ Corporation; and Becton Dickinson and Company, with the aim of creating a new way for community doctors to decide on the most effective treatments for colon cancer using the latest next generation sequencing technology as well as artificial intelligence-based decision support algorithms. Over the 18 month period, EKF's PrecisionPath™ will be used to determine the genetic profiles of tumour samples provided by the Institute for Translational Oncology Research, which is part of Greenville Health Systems' Cancer Institute. At the same time DecisionQ will employ its advanced machine-learning platform to integrate the genetic profile data with existing clinical annotations and the known outcomes of the patient samples to validate the treatment indicated by the genetic profiling. If the results successfully correlate, then this will help validate EKF's PrecisionPath™ product in being able to improve clinical decisions related to the treatment of colon cancer patients.

EKF Diagnostics Holdings plc, 2014 Earnings Call, Mar 16, 2015

EKF Diagnostics Holdings plc, 2014 Earnings Call, Mar 16, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKF:LN 23.00 GBp +0.25

EKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EKF.
View Industry Companies
 

Industry Analysis

EKF

Industry Average

Valuation EKF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKF DIAGNOSTICS HOLDINGS PLC, please visit www.ekfdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.